Non-Invasive Prenatal Testing Market

Report ID : 1425 | Published : 2022-10-29 | Pages: 178 | Format: PDF/EXCEL

The market size of the global non-invasive prenatal testing market in the year 2021 is valued at 3.77 billion and is predicted to reach 10.54 billion by the year 2030 at an 12.33% CAGR during the forecast period.

Non-invasive prenatal testing, often known as non-invasive prenatal screening, is a method for determining the likelihood that a fetus will have genetic abnormalities. This type of screening is risk-free and remarkably successful for Down syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, and other genetic conditions. By week 10 of pregnancy, little DNA fragments are detected in pregnant women's blood, which is frequently examined. Reduced fertility, high blood pressure, increased risk of miscarriage, stillbirths, and maternal mortality are just a few health problems that might arise as a mother ages. Maternal age can also increase the likelihood of genetic disorders in babies due to incorrect chromosomal division. The demand for non-invasive prenatal diagnostics is therefore anticipated to increase as maternal age and the prevalence of chromosomal disorders both rise. The market's organic revenue growth is driven by an increase in the majority of chromosomal abnormalities and increased product usage in new applications. Additionally, improvements in existing tests' chemistry, usefulness, and bioinformatics analysis are anticipated to fuel market expansion. The market for non-invasive prenatal testing is driven by older women's more significant chance of having infants with Down syndrome.

Furthermore, the rise in children with chromosomal problems and advancements in diagnostic imaging technology drives the demand for non-invasive prenatal testing. The market for non-invasive prenatal diagnostics is anticipated to benefit from expanding insurance coverage for typical and low-risk pregnancies. However, the high cost of testing and provisional diagnostic tools restricts the market's growth. Two more issues that could impede the expansion of the global non-invasive prenatal testing market are the decreased per capita healthcare spending and the inadequate test reimbursement policies.

Market Segmentation:

The non-invasive prenatal testing market is segmented on method, end-use and application. Based on process, the market is segmented into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests and others. Based on the end-user, the market is segmented into diagnostic laboratories, hospitals, research centres and clinics. Based on the application, the market is segmented into trisomy, microdelection syndrome and others.

The cell-free DNA in maternal plasma tests category dominated the market in 2021. Various genetic tests are increasingly used in prenatal care to forecast the likelihood of genetic abnormalities. With the advent of whole-genome sequencing, technological developments have broadened the scope of testing and made it possible to identify many more chromosomal abnormalities, including microdeletions and sex-specific ones. However, the use of ultrasound detection as a complement to the NIPT test based on cell-free DNA results in a lower market share. However, more recent technological developments and 3D-4D imaging have enhanced the test's real-time monitoring, safety, and efficacy, which is further likely to fuel the segment's expansion.

The trisomy category witnessed growth at a rapid rate.

The trisomy category dominated the market in 2021 because of increased chromosomal abnormalities. The prevalence of genetic illnesses is high in India. According to much research, trisomy 21 (down syndrome), which has a high incidence rate of 1 in 800 births and results in the birth of 32,000 children with down syndrome every year, is discovered in 1 in 166 newborns nationwide. Whole genome sequencing tests are now available, and they can identify a wide range of additional chromosomal abnormalities, including microdeletions and sex-specific ones.

The North American non-invasive prenatal testing market holds a significant regional revenue share.

The North American non-invasive prenatal testing market is expected to register the highest market share in revenue shortly. This can be attributable to several factors, including the high preterm birth rate, the developed healthcare system, and the rising maternal mortality rate. The prevalence of chromosomal abnormalities is rising, as is public awareness of the advantages of non-invasive prenatal testing. These factors are driving the market's expansion. The demand for non-invasive prenatal testing is increasing significantly due to the top firms' increased focus on diversifying their product lines, boosting the market's growth. In addition, the development of new, technologically sophisticated tests has a significant impact on the market expansion in this region. In addition, Asia Pacific is projected to grow rapidly in the global non-invasive prenatal testing market because of the expanding healthcare systems in developing nations like China and India, among others. Rising public healthcare spending and increased knowledge of non-invasive prenatal testing will be projected to boost market expansion. Additionally, non-invasive prenatal testing developments and technology improvements are anticipated to drive the market's growth during the projection period.

Competitive Landscape

Key players in the non-invasive prenatal testing market are Yourgene Health, Illumina Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, GE Healthcare, PerkinElmer Inc., BGI and Natera Inc.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Non-Invasive Prenatal Testing Market Snapshot

Chapter 4. Global Non-Invasive Prenatal Testing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Method Type Estimates & Trend Analysis

5.1. by Method Type & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Method Type:

5.2.1. Ultrasound Detection

5.2.2. Biochemical Screening Tests

5.2.3. Cell-free DNA in Maternal Plasma Test

5.2.4. Others

Chapter 6. Market Segmentation 2: by End-use Estimates & Trend Analysis

6.1. by End-use & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by End-use:

6.2.1. Diagnostic Laboratories

6.2.2. Hospitals

6.2.3. Research Centers

6.2.4. Clinics

Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis

7.1. by Application & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Application:

7.2.1. Trisomy

7.2.2. Microdelection Syndrome

7.2.3. Others

Chapter 8. Non-Invasive Prenatal Testing Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method Type, 2022-2030

8.1.2. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-use, 2022-2030

8.1.3. North America Non-Invasive Prenatal Testing Market revenue (US$ Million) by Application, 2022-2030

8.1.4. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.2. Europe

8.2.1. Europe Non-Invasive Prenatal Testing Market revenue (US$ Million) by Method Type, 2022-2030

8.2.2. Europe Non-Invasive Prenatal Testing Market revenue (US$ Million) by End-use, 2022-2030

8.2.3. Europe Non-Invasive Prenatal Testing Market revenue (US$ Million) by Application, 2022-2030

8.2.4. Europe Non-Invasive Prenatal Testing Market revenue (US$ Million) by country, 2022-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Non-Invasive Prenatal Testing Market revenue (US$ Million) by Method Type, 2022-2030

8.3.2. Asia Pacific Non-Invasive Prenatal Testing Market revenue (US$ Million) by End-use, 2022-2030

8.3.3. Asia-Pacific Non-Invasive Prenatal Testing Market revenue (US$ Million) by Application, 2022-2030

8.3.4. Asia Pacific Non-Invasive Prenatal Testing Market revenue (US$ Million) by country, 2022-2030

8.4. Latin America

8.4.1. Latin America Non-Invasive Prenatal Testing Market revenue (US$ Million) by Method Type, 2022-2030

8.4.2. Latin America Non-Invasive Prenatal Testing Market revenue (US$ Million) by End-use, 2022-2030

8.4.3. Latin America Non-Invasive Prenatal Testing Market revenue (US$ Million) by Application, 2022-2030

8.4.4. Latin America Non-Invasive Prenatal Testing Market revenue (US$ Million) by country, 2022-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Non-Invasive Prenatal Testing Market revenue (US$ Million) by Method Type, 2022-2030

8.5.2. Middle East & Africa Non-Invasive Prenatal Testing Market revenue (US$ Million) by End-use, 2022-2030

8.5.3. Middle East & Africa Non-Invasive Prenatal Testing Market revenue (US$ Million) by Application, 2022-2030

8.5.4. Middle East & Africa Non-Invasive Prenatal Testing Market revenue (US$ Million) by country, 2022-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Yourgene Health

9.2.2. Illumina Inc.

9.2.3. Agilent Technologies Inc.

9.2.4. Thermo Fisher Scientific Inc.

9.2.5. F. Hoffmann-La Roche Ltd.

9.2.6. Laboratory Corporation of America Holdings

9.2.7. GE Healthcare

9.2.8. PerkinElmer Inc.

9.2.9. BGI

9.2.10. Natera Inc.

9.2.11. Other Prominent Players

Segmentation of Non-Invasive Prenatal Testing Market-

By Method-

  • Ultrasound Detection
  • Biochemical Screening Tests
  • Cell-free DNA in Maternal Plasma Test
  • Others

By End-Use-

  • Diagnostic Laboratories
  • Hospitals
  • Research Centers
  • Clinics

By Application-

  • Trisomy
  • Microdelection Syndrome
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

 

Need Complete Report ?
Our Clients